Physician profile
Varqa Rouhipour
NPI 1457367286
$4,515.03
in general payments reported to CMS, 2019-2025
10 companies · $2,461 in 2025
The $2,461 reported for 2025 was more than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $754 · 2022: $1,274 · 2023: $25.25 · 2025: $2,461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,246 · Travel and Lodging: $1,235 · Education: $6.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,245.65 |
| Travel and Lodging | $1,234.91 |
| Education | $6.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impactortho, INC. | $1,903.34 | 2022-2025 | |
| Arthrex, INC. | $1,101.37 | 2025 | |
| Medtronic USA, INC. | $713.27 | 2019 | |
| Stryker Corporation | $343.50 | 2025 | Gamma, Axsos, Osteoset |
| Zimmer Biomet Holdings, INC. | $164.10 | 2019-2025 | Tapestry |
| Depuy Synthes Sales INC. | $136.18 | 2022-2025 | Actis, Tfn-Advance, Na |
| Medical Device Business Services, INC. | $106.42 | 2025 | Actis |
| Smith+Nephew, INC. | $25.25 | 2023 | Evos |
| Core Surgical Group | $21.60 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$101,750.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Varqa Rouhipour listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.